DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/504cfd/australia_pharmace) has announced the addition of the "Australia Pharmaceutical Market Overview - Reforms and continued price cuts will change the healthcare landscape" report to their offering.
Australia Pharmaceutical Market Overview - Reforms and Continued Price Cuts Will Change the $80 Billion Healthcare Landscape
The prescription pharmaceutical market in Australia was valued at $9.1 billion in 2009. Key growth drivers include the growing use of chronic high-value innovative treatments driven by a rising elderly population and high public spending as a proportion of total healthcare expenditure.
- Overview of Australia's socioeconomics and demographics, healthcare system, regulation, pricing and reimbursement and intellectual property position.
- Assesses the size of Australia's pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies.
- Examines Australia's generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree of brand erosion.
- Quantifies Australia's R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics and domestic M&A analysis.
Highlights of this title
- Australia's health expenditure totaled $81.8 billion, representing 9.1% of gross domestic product (GDP) in the financial year of 2007-08, which is the same percentage of GDP as the previous year. Australia's health expenditure as a proportion of GDP has been comparable to that seen in Europe, with most of its spending coming from the government.
- Lipitor (atorvastatin, Pfizer) generated significantly higher sales than any other brand on the Australian pharmaceutical market in 2009 ($550m). The second and third highest-selling brands, Crestor (rosuvastatin; AstraZeneca) and Nexium (esomeprazole; AstraZeneca), lag far behind Lipitor and did not even reach half of its sales.
- Compared with Europe, where 17 biosimilars of five different molecules have been approved since 2006, Australia's biosimilar market is small, particularly in terms of sales at $45,000. Somatropin is the only biologic that has biosimilar versions available, although the market is still very much dominated by the original branded product.
Key reasons to purchase this title
- Evaluate the evolving regulatory landscape and the impact of pricing and reimbursement controls on market access.
- Quantify the size and growth of the prescription pharmaceutical market in Australia, analyzing key therapy areas, brands and companies.
- Assess drivers and resistors of generic and biosimilars uptake in Australia and the level of erosion brands can expect to face post patent expiry.
Key Topics Covered:
1. Australia - Executive Summary 2. Australia - Socio-demographic and economic Analysis
3. Australia - Healthcare system and drug regulatory analysis
4. Australia - Prescription pharmaceutical sales analysis 5. Australia - Drug expiry analysis
6. Australia - Pharmaceutical industry infrastructure analysis
- Merck & Co.
- Johnson & Johnson
- Sigma Pharmaceuticals
For more information visit http://www.researchandmarkets.com/research/504cfd/australia_pharmace
Research and Markets
Laura Wood, Senior Manager,
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
KEYWORDS: Australia Australia/Oceania
INDUSTRY KEYWORDS: Health Pharmaceutical